InvestorsHub Logo
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

Re: marthambles post# 17181

Tuesday, 05/02/2017 12:10:14 PM

Tuesday, May 02, 2017 12:10:14 PM

Post# of 20689

Any theories about what's driving today's price rise?

• MNTA is talking to multiple prospective partners re M923. (This is not really new info, but it hadn’t been mentioned in a while.)

• Possibility of 40mg-Glatopa approval before year-end is perhaps larger than investors thought after NVS took 40mg Glatopa out of 2017 guidance on its own 1Q17 CC.

• MNTA claims to have a commercialization path for M834 (Orencia) despite losing the recent IPR on BMY’s sub-Q-formulation patent.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”